No 340B Savings for Transgender Care Act

HR 2197, the "No 340B Savings for Transgender Care Act," prohibits covered entities participating in the federal 340B drug pricing program from using savings from discounted drug purchases to pay for specific transgender healthcare services. The bill amends the Public Health Service Act to ban using 340B savings for sex reassignment surgeries or hormone treatments provided "for the purpose of gender alteration" of transgender individuals. This directly affects hospitals and clinics enrolled in the 340B program, restricting how they allocate funds saved through the program’s discounted drug pricing. The key provision is a targeted restriction on fund usage, not a ban on providing the medical services themselves. The bill focuses on reallocating program savings away from these specific care types.